No matching parts found
The United Arab Emirates and Israel are committed to executing in combination a revolutionary solution to stumble upon COVID-19 in 30 to 60 seconds. Photo Twitter
The Scent Check device detects a mixture of volatile biological compounds, or “VOC Signature,” of exhaled nasal air that is derived from the host’s reaction to SARS-CoV-2 infection. The air pattern is captured transparently through an “air trap”, a small bag supplied with a straw in which the control subject must blow nasal air. A device learning style is then used to analyze, diagnose, and tag the VOC signature and provide the verification result in 30 to 60 seconds.
The non-invasive nature and speed of effects give Scent Check the perspective of the worldwide diagnostics industry. The solution enables testing in giant and small environments, without the need for complex and cost-effective infrastructure.
The leaders of the two corporations participated in a rite of signature organized through a videoconvention between the United Arab Emirates and Israel. During the event, we discussed how to leverage the experience and respective technologies to drive the release of the solution in a phase where, given the lack of vaccine, the maximum effectiveness in breaking COVID-19 transmission patterns is massive testing.
Ashish Koshy, CEO of G42 Healthcare, said: “At G42 Healthcare, we are at the forefront of the war opposed to COVID-19 and are committed to creating cutting-edge systems and responses and protecting public health. This collaboration with NanoScent, we will load some other solution resistant to our comprehensive diagnostic portfolio, which already includes PCR and LamPORE tests. The partnership also reaffirms the desire to fight the COVID-19 pandemic through a joint global effort in which more productive action organizations share their expertise and technologies to gain benefits from society.
Oren Gavriely, CEO of NanoScent, said: “In 2009, I drove from New York to Washington DC for a convention organized across Jordan. Many corporations were presenting progress in the Middle East and I knew that Israel is not a component of the Middle East. in many ways. I have proposed the purpose of bringing Israel to the Middle East and I have done so through many local activities in Israel. Today, NanoScent has the ability to help redefine the Middle East by offering state-of-the-art Covid-19 detection of technologies to open borders.
G42 Healthcare, which recently led operations of the world’s first Phase III clinical trial for the inactivated COVID-19 vaccine and other population-wide programs, will conduct thousands of tests of the new solution in the coming weeks to validate its effectiveness. and increase its accuracy before its release to the market.
Wam